Abstract
The gonads in both sexes serve the same dual functions, namely, the production of gametes and sex steroids. These functions are clinically quiescent in children but subsequently are induced at puberty and then maintained through much of adulthood by the glycoprotein pituitary gonadotropins leutinizing hormone (LH) and follicle-stimulating hormone (FSH). By historical convention these names refer to events and structures within the ovary, but their structures are identical in both men and women and their functions in each gender are largely similar. The secretions of these gonadotropins are largely regulated by classic feedback inhibition from circulating gonadal products, with LH being excreted by the sex steroid levels in blood and FSH by proteins (inhibins) produced by developing gametes (Fig. 1). When inadequate gonadal function results from a defect within the gonad itself, the condition is referred to as primary gonadal failure. Hypogonadism resulting from pituitary or hypothalamic defects is referred to as secondary and tertiary gonadal failure, respectively. Despite the later distinction, many authors continue to refer to either pituitary or hypothalamic failure as secondary or “central” hypogonadism.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Tansey MJ, Schlechte JA. Pituitary production of prolactin and prolactin-suppressing drugs. Lupus 2001:10:660–664.
Loprinzi CL, Michalak JC, Quella SK. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347–352.
Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788–793.
Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17–22.
David A, Don R, Tajchner G, Weissglas L. Veralipride: alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 1988;158:1107–1115.
Moghissi KS. Hormone replacement therapy for menopausal women. Compr Ther 2000;26:197–202.
Yaffe K. Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence? Ann NY Acad Sci 2001;949:215–222
Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001;15:797–817
Bachmann G. Physiologic aspects of natural and surgical menopause. J Reprod Med 2001;46(3 suppl):307–315.
Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933–941.
Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102–1109.
Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987;70:289–293.
Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75–78.
Psaty BM, Hackbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogen and progestin in postmenopausal women. Arch Intern Med 1994;154:1333–1339.
Hulley S, Grady, D Bush T, et al., for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605–613.
Cherry N. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002;360:2001–2008.
Manson JE, Martin KA. Clinical practice. Postmenopausal hormone-replacement therapy. N Engl J Med 2001;345:34.
Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499.
Writing group for the Women’s Health Initiative investigators, Risks and benefits of estrogen plus progestin in healthy women; Principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002;288:321–333.
Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065–1079.
Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999;131:935–942.
Bardin CW, Lipsett MB. Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 1967;46:891.
Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682–688.
Watts, NB, Notelovitz, M, Timmons, MC, et al. Comparison of oral estrogens and estrogen plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529.
Benvenga S, Campenni A, Ruggeri RM, Trimarchi F. Hypopituitarism secondary to head trauma. J Clin Endocrinol Metab 2000;85:p-1361.
Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589–598.
Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239–242.
Summary of the Consensus Session from the 1st Annual Andropause Consensus 2000 Meeting, the Endocrine Society.
Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002;87:136–143.
Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997;82:3793–3796.
Viallard JF, Marit G, Mercie P, Leng B, Reiffers J, Pellegrin JL. Polycythaemia as a complication of transdermal testosterone therapy. Br J Haematol 2000;110:237–238.
Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469–3478
Bhasin S, ed. The Endocrine Society Clinical Bulletins in Andropause: Benefits and Risks of Treating Hypogonadism in the Aging Male, no. 2, 2002.
Gambineri A, Pasquali R. Testosterone therapy in men: clinical and pharmacological perspectives. J Endocrinol Invest 2000;23:196–214
Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol 2000;161:73–88.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
MacIndoe, J.H. (2003). Hypogonadism in Men and Women. In: Bar, R.S. (eds) Early Diagnosis and Treatment of Endocrine Disorders. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-378-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-59259-378-1_17
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-414-2
Online ISBN: 978-1-59259-378-1
eBook Packages: Springer Book Archive